// App-Quantinova.ai

: PBI-4050 Therapy Selectively Improves Pulmonary Hypertension, Lung Remodeling and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction

Researchers

Presenter

  • L. Gagnon

Principal Investigators

  • Q. T. Nguyen

  • B. Grouix

  • A. Laverdure

  • P. Laurin

  • M. Sirois

  • A. Calderone

  • J. C. Tardif

  • Y. Shi

  • J. Dupuis

Medical Centers

  • Prometic Biosciences Inc., Laval, QC, Canada.

  • Institut de Rhumatologie, Montreal, QC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • PBI4050

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved